Supriya Srivastava

Senior Research Fellow

National University Singapore Yong Loo Lin School of Medicine
Country flagSingapore

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (9)

Intestinal metaplasia (IM) is a premalignant condition associated with increased risk of gastric cancer—a deadly malignancy with varying geographic incidence. High-depth targeted sequencing of more than 1,500 IM samples from six countries identified 47 significantly mutated genes, including driver genes associated with high-risk populations and worse prognosis (ARID1A), KRAS/MAPK signaling (KRAS, BRAF, MAP2K1, MAP3K1, and MAP2K4), and altered mucosal immunity (PIGR). IM whole-genome sequencing and DNA methylation analysis revealed SBS17 as a specific mutational signature separating IMs from normal gastric tissues, associated with late DNA replication, genomic hypomethylation, and tobacco exposure. Beyond epithelial-derived somatic mutations, we observed elevated clonal hematopoiesis (CH) in patients with IM associated with age, smoking, and enhanced risk of progressing to gastric cancer. Patients with CH expansions exhibited co-occurring IM PIGR truncating mutations and greater colonization of the IM microenvironment by orally derived bacteria, suggesting that CH may promote IM progression by modulating host–microbe mucosal immunity. Significance: This international study identifies recurrent IM driver genes, IM-specific mutational signatures, and alterations in IM-associated immune landscapes and microbiomes. Our results highlight a role for nonepithelial somatic alterations (CH) in IM progression to gastric cancer, offering new translational opportunities for early cancer detection and interception.

Year:

2026

Year:

2026

Purpose: Peritoneal metastases (PM) in colorectal cancer portend a poor prognosis. We sought to elucidate molecular features differentiating primary tumors (PT) from PMs and actionable targets facilitating transcoelomic dissemination and progression. Experimental Design: We performed multiomic profiling of 227 samples from 136 patients, including 56 PTs and 120 synchronous PMs comprising 34 matched PT–PM pairs. Whole-exome and bulk RNA sequencing analyses were conducted to identify underlying genomic aberrations and transcriptomic differences between primary and peritoneal lesions. We spatially characterized the microenvironment of tumor–stroma compartments and studied the roles of stromal phenotypes in promulgating tumorigenesis. Results: Whole-exome sequencing found that genomic alterations and clonality patterns between PTs and PMs remain broadly similar. Transcriptomic profiles, however, suggest a transition as tumors reach the peritoneum toward a more mesenchymal tumor profile and fibrotic tumor microenvironment. Applying spatial profiling, we identify a fibro-collagenous and immune-infiltrated stromal phenotype [stromal cluster (SC) 2] characterized by increased cancer-associated fibroblasts, memory B cells, M2 macrophages, and T-cell exhaustion. These findings were orthogonally validated by multiplex IHC. Patients with SC2 stroma had poorer survival and were characterized by high SERPINE-1 (PAI-1) expression. PMs in patients with SC2 stroma were associated with enriched oncogenic pathways such as TGF-β. PAI-1 inhibition of colorectal cancer PM cell lines with a novel biologic demonstrated reduced IL2–STAT5 and TGF-β pathways and cell death. Conclusions: Our findings unveil distinctive and actionable molecular signatures, offering deeper insights into the intricate cross-talk between tumor cells and stromal microenvironments enabling PM in colorectal cancer.

Year:

2025

Gastric cancer is a major cause of global cancer mortality. To explore geospatial interactions in gastric tumors, we integrated 2,138 spatial transcriptomic regions of interest with 152,423 single-cell expression profiles across 226 cancer samples from 121 patients. We observed pervasive expression-based intratumor heterogeneity, recapitulating tumor progression through spatially localized and functionally ordered subgroups associated with specific immune microenvironments, checkpoint profiles, and genetic drivers (SOX9). Phylogenetic analysis revealed two separate evolutionary trajectories (branched evolution and internal diaspora evolution) associated with distinct molecular subtypes, clinical prognoses, and stromal neighborhoods, including VWF+ ACKR1+ endothelial cells. Spatial analysis of tumor–stroma interfaces across multiple gastric cancers highlighted new ecosystem states not attributable to mere tumor/stroma admixture, landmarked by increased GREM1 expression. Our results provide insights into how the cellular ecosystems of individual gastric cancers are sculpted by tumor-intrinsic and extrinsic selective pressures, culminating in individualized patient-specific cancer cartographies. Significance: Integration of spatial transcriptomic (GeoMx Digital Spatial Profiler) and single-cell RNA sequencing data from multiple gastric cancers identifies spatially resolved expression-based intratumoral heterogeneity, associated with distinct immune microenvironments. We uncovered two separate evolutionary trajectories associated with specific molecular subtypes, clinical prognoses, stromal neighborhoods, and genetic drivers. Tumor–stroma interfaces emerged as a unique state of tumor ecology.

Year:

2025

Supplementary Methods 1. Supplementary Methods, DNA extraction and whole exome sequencing, Mutation calling and mutational signatures, Whole transcriptome sequencing, Spatial profiling, Methods of A5 Discovery and Validation, Other statistical methods and reproducibility.

Year:

2025

Purpose: Peritoneal metastases (PM) in colorectal cancer portend a poor prognosis. We sought to elucidate molecular features differentiating primary tumors (PT) from PMs and actionable targets facilitating transcoelomic dissemination and progression. Experimental Design: We performed multiomic profiling of 227 samples from 136 patients, including 56 PTs and 120 synchronous PMs comprising 34 matched PT–PM pairs. Whole-exome and bulk RNA sequencing analyses were conducted to identify underlying genomic aberrations and transcriptomic differences between primary and peritoneal lesions. We spatially characterized the microenvironment of tumor–stroma compartments and studied the roles of stromal phenotypes in promulgating tumorigenesis. Results: Whole-exome sequencing found that genomic alterations and clonality patterns between PTs and PMs remain broadly similar. Transcriptomic profiles, however, suggest a transition as tumors reach the peritoneum toward a more mesenchymal tumor profile and fibrotic tumor microenvironment. Applying spatial profiling, we identify a fibro-collagenous and immune-infiltrated stromal phenotype [stromal cluster (SC) 2] characterized by increased cancer-associated fibroblasts, memory B cells, M2 macrophages, and T-cell exhaustion. These findings were orthogonally validated by multiplex IHC. Patients with SC2 stroma had poorer survival and were characterized by high SERPINE-1 ( PAI-1 ) expression. PMs in patients with SC2 stroma were associated with enriched oncogenic pathways such as TGF-β. PAI-1 inhibition of colorectal cancer PM cell lines with a novel biologic demonstrated reduced IL2–STAT5 and TGF-β pathways and cell death. Conclusions: Our findings unveil distinctive and actionable molecular signatures, offering deeper insights into the intricate cross-talk between tumor cells and stromal microenvironments enabling PM in colorectal cancer.

Year:

2025

Gastric cancer is a major cause of global cancer mortality. To explore geospatial interactions in gastric tumors, we integrated 2,138 spatial transcriptomic regions of interest with 152,423 single-cell expression profiles across 226 cancer samples from 121 patients. We observed pervasive expression-based intratumor heterogeneity, recapitulating tumor progression through spatially localized and functionally ordered subgroups associated with specific immune microenvironments, checkpoint profiles, and genetic drivers ( SOX9 ). Phylogenetic analysis revealed two separate evolutionary trajectories (branched evolution and internal diaspora evolution) associated with distinct molecular subtypes, clinical prognoses, and stromal neighborhoods, including VWF + ACKR1 + endothelial cells. Spatial analysis of tumor–stroma interfaces across multiple gastric cancers highlighted new ecosystem states not attributable to mere tumor/stroma admixture, landmarked by increased GREM1 expression. Our results provide insights into how the cellular ecosystems of individual gastric cancers are sculpted by tumor-intrinsic and extrinsic selective pressures, culminating in individualized patient-specific cancer cartographies. Significance: Integration of spatial transcriptomic (GeoMx Digital Spatial Profiler) and single-cell RNA sequencing data from multiple gastric cancers identifies spatially resolved expression-based intratumoral heterogeneity, associated with distinct immune microenvironments. We uncovered two separate evolutionary trajectories associated with specific molecular subtypes, clinical prognoses, stromal neighborhoods, and genetic drivers. Tumor–stroma interfaces emerged as a unique state of tumor ecology.

Year:

2025

(1) Supplementary Figure 1 shows morphologies of different ROI categories and their representative genes, pathways and similarities with paired scRNA-seq data. (2) Supplementary Figure 2 shows validation of findings from the discovery GeoMx DSP cohort in the whole-section GeoMx DSP cohort and also the TMA GeoMx DSP cohort. (3) Supplementary Figure 3 shows experiments validating that intratumor G1/G2 subregion expression is tumor-intrinsic using multiplexed IHC, Stereoseq spatial transcriptomics, and in vitro Stereoseq drug treatment profiling. (4) Supplementary Figure 4 shows expression of individual immune checkpoints, chemokines, cytokines, molecular signatures (immune exhaustion, intracellular signaling) and emerging therapeutic targets in G1 and G2 subregions in the discovery and validation cohort. (5) Supplementary Figure 5 shows experiments validating that G2 RNA-ITH subregions have higher CNV burdens than G1 subregions using signature scores, CNV calling from scRNA-seq, and validation using WES and Stereoseq data. (6) Supplementary Figure 6 shows phylogenetic analysis and trajectory analysis of scRNA-seq tumor subgroups using various methods. (7) Supplementary Figure 7 shows survival analysis and multi-variate analysis validating that internal diaspora GC is associated with worse prognosis in various cohorts. (8) Supplementary Figure 8 shows functional validation experiments for the potential G2 markers SOX9, AGR2 and TSPAN8 using CellOracle, RNAi and CRISPR knock out assays. (9) Supplementary Figure 9 shows typical pathways, markers and cell types for tumor-stroma interface ROIs.

Year:

2025

(1) Supplementary Table 1 shows GeoMx DSP ROI and scRNA-seq characteristics of samples profiled; (2) Supplementary Table 2 shows clinical characteristics of GeoMx DSP ROI and scRNA-seq samples profiled; (3) Supplementary Table 3A shows consistency between before and after batch effect removal on top enriched pathways in various ROI categories, 3B shows consistency between before and after batch effect removal on G1 and G2 labels on Tumor ROIs; (4) Supplementary Table 4 shows Silhouette scores of using different number of clusters in Tumor ROI hierarchical clustering; (5) Supplementary Table 5 shows detailed information of GeoMx ROIs in the TMA cohort; (6) Supplementary Table 6 shows top DEGs for endothelial cell subtypes (Endo1-Endo3); (7) Supplementary Table 7 shows top DEGs for macrophage cell subtypes (TAM1-TAM6); (8) Supplementary Table 8 shows top DEGs for fibroblast cell subtypes (Fib1-Fib4).

Year:

2025

Collaborators (17)

Sun Young Rha

Yonsei University College of Medicine

SOUTH KOREA
View details

Samuel Klempner

Associate Professor

Massachusetts General Hospital

UNITED STATES
View details

Joseph J Zhao

National University of Singapore

SINGAPORE
View details

Wai Leong Tam

Associate Professor (Adjunct)

National University Singapore Yong Loo Lin School of Medicine

SINGAPORE
View details

Heike I Grabsch

Professor

University of Leeds

UNITED KINGDOM
View details

Raghav Sundar

Associate Professor

Yale University

UNITED STATES
View details

Chang Xu

Senior Research Fellow

Duke-NUS Medical School

SINGAPORE
View details

Allison Chan

National University of Singapore

SINGAPORE
View details

Haoran Ma

National University of Singapore

SINGAPORE
View details

Filippo Pietrantonio

Researcher (non-academic)

Fondazione IRCCS Istituto Nazionale dei Tumori

ITALY
View details

Lit-Hsin Loo

Senior Principal Investigator

ImmunoQs Pte Ltd

SINGAPORE
View details

Federica Morano

Fondazione IRCCS Istituto Nazionale dei Tumori

ITALY
View details

Jonathan Lee

National University Hospital

SINGAPORE
View details

Jolene Wong

Clinical Assistant Professor & Consultant

Singapore General Hospital

SINGAPORE
View details

Maarten F. Bijlsma

Staff scientist

Academic Medical Center

NETHERLANDS
View details

Xing KANG

Dean's Postdoctoral Fellow

Nanyang Technological University

SINGAPORE
View details

Louis Vermeulen

Group leader / PI

-

NETHERLANDS
View details